Neurocrine Biosciences, Inc.
NBIX
$108.31
$1.311.22%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.90% | 5.40% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 0.90% | 5.40% | |||
| Cost of Revenue | -3.99% | 1.35% | |||
| Gross Profit | 3.27% | 7.49% | |||
| SG&A Expenses | 28.81% | -3.18% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.58% | -1.13% | |||
| Operating Income | -29.11% | 24.95% | |||
| Income Before Tax | -14.56% | 93.00% | |||
| Income Tax Expenses | -1.65% | 80.06% | |||
| Earnings from Continuing Operations | -20.57% | 99.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -20.57% | 99.69% | |||
| EBIT | -29.11% | 24.95% | |||
| EBITDA | -27.81% | 23.26% | |||
| EPS Basic | -19.70% | 99.12% | |||
| Normalized Basic EPS | -25.46% | 21.61% | |||
| EPS Diluted | -19.27% | 96.83% | |||
| Normalized Diluted EPS | -25.27% | 21.50% | |||
| Average Basic Shares Outstanding | -1.09% | 0.30% | |||
| Average Diluted Shares Outstanding | -1.34% | 0.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
